INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) from its SEC filings: 2025 revenue $1.6 billion (+2% vs the year before), net margin -32%, free cash flow -$31.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $1.6 billion |
| Revenue growth | +2% |
| Net income | -$516.8 million |
| Net margin | -31.6% |
| Free cash flow | -$31.1 million |
| Diluted EPS | $-6.74 |
| Latest quarter (Q3 2026 (calendar)) revenue vs a year earlier | +2% |
| Cash | $252.3 million |
| Long-term debt | $697.5 million |
| Share count, 1 year | -0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.